Treatment for Pancreatic Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pancreatic Cancer
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether SBRT is better than conventional radiation therapy when given with chemotherapy for patients with inoperable lung cancer.

Eligible Conditions
  • Pancreatic Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 8 weeks postradiation

8 weeks postradiation
The number of subjects who present with node-positive disease following surgical resection.

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

102 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks postradiation

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
566 Previous Clinical Trials
1,154,058 Total Patients Enrolled
William Hall, MDPrincipal Investigator - Medical College of Wisconsin
Froedtert & The Medical College of Wisconsin
2 Previous Clinical Trials
317 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
This means that the tumor must be confirmed as adenocarcinoma, the tumor must be resectable, borderline resectable, or locally advanced, and it must be based on institutional standardized criteria and tumor board review.
Patients who have or do not have regional adenopathy are eligible.
candidacy for the study is based on the presence or absence of radiographically detectable metastatic disease
A patient's history and physical examination, including the collection of weight and vital signs, will be done within 30 days prior to the start of treatment.
The patient must have a CT scan or MRI of the abdomen and pelvis with contrast and diffusion-weighted sequences done within 30 days of the study.
The person must have a chest CT scan or X-ray within 30 days prior to study entry.
Eastern Cooperative Oncology Group (ECOG) performance status must be 0-2 within 14 days of randomization.
A person has an absolute neutrophil count (ANC) of ≥ 1,000 cells/mm3 if their white blood cell count is ≥ 1,000 cells/mm3.